AbbVie’s Elahere shows positive results in Phase II trial for platinum-sensitive ovarian cancer.

AbbVie's investigational therapy, Elahere, demonstrated promising results in a Phase II trial for platinum-sensitive ovarian cancer. The study showed a 62.7% objective response rate and an 81% progression-free rate among patients. Elahere's combination with carboplatin and subsequent monotherapy offers a potential new treatment option.

AbbVie's investigational therapy, Elahere (mirvetuximab soravtansine-gynx), has shown notable effectiveness in a Phase II clinical study targeting patients with platinum-sensitive ovarian cancer (PSOC). The IMGN853-0420 trial (NCT05456685) evaluated the therapeutic impact of Elahere in combination with carboplatin, followed by Elahere monotherapy, producing an overall objective response rate (ORR) of 62.7% among the study population.

Study Structure and Findings

The Phase II research focused on individuals with recurrent PSOC expressing folate receptor alpha (FR). The study included two distinct phases: an induction period combining Elahere and carboplatin, and a subsequent maintenance phase using Elahere alone. The principal outcomes from the trial include:

• Objective Response Rate (ORR): 62.7% within the FR 50% subgroup, with a comparable 62.4% ORR across all participants.
• No Disease Progression: 81% of the 125 enrolled patients showed no disease progression while continuing Elahere monotherapy.
• Monotherapy Effectiveness: Among patients transitioning to Elahere alone, the ORR reached 68%.
• Duration of Response (DoR): The median DoR was 11.2 months for the entire patient cohort.

The trial results suggest that Elahere, when administered as part of a combination regimen followed by monotherapy, delivers meaningful therapeutic benefit for patients with this challenging ovarian cancer subtype. The safety profile observed was consistent with prior clinical findings, with no new safety concerns reported.

Leadership Perspective

Dr. Daejin Abidoye, Vice President and Head of Oncology, Solid Tumor and Hematology at AbbVie, emphasized the importance of these findings, noting that platinum-sensitive ovarian cancer, while responsive to chemotherapy, becomes increasingly difficult to manage with each recurrence due to declining efficacy of standard treatments and cumulative toxicities. He highlighted that Elahere offers a potential new option for patients facing these challenges.

Conference Presentation

These findings were presented during an oral session at the 2026 Society of Gynecologic Oncology (SGO) Annual Meeting in San Juan, Puerto Rico, from April 10 to 13, 2026. The presentation provided an opportunity for oncologists, researchers, and industry experts to examine emerging advancements in ovarian cancer therapy.

Next Steps: Phase III Trials and Regulatory Status

AbbVie is progressing to a Phase III clinical trial (NCT05445778) evaluating Elahere combined with bevacizumab versus bevacizumab alone for maintenance therapy in patients with FR-expressing platinum-sensitive ovarian cancer. Previous regulatory approvals for Elahere include the US Food and Drug Administration in March 2024 and the European Commission in November 2024 for treatment of platinum-resistant ovarian cancer.

Market Projections

GlobalData forecasts significant commercial potential for Elahere, estimating sales could reach $2.6 billion by 2032. The broader ovarian cancer market across the seven major pharmaceutical markets (7MM) is also expected to grow from $3.3 billion in 2022 to $4.1 billion in 2032. This trend reflects increasing demand for effective treatments in both platinum-sensitive and platinum-resistant ovarian cancer subtypes, where therapeutic options remain limited.

Sources:

• AbbVie’s Elahere shows positive results in Phase II trial for platinum-sensitive ovarian cancer
• AbbVie’s Elahere Shows Positive Results in Phase II Trial for Platinum-Sensitive Ovarian Cancer
• AbbVie’s Elahere Phase II trial results show promise in ovarian cancer
• AbbVie’s Elahere succeeds in Phase II platinum-sensitive ovarian cancer trial